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Ginsenoside Re protects
methamphetamine-induced dopaminergic
neurotoxicity in mice via upregulation of
dynorphin-mediated κ-opioid receptor and
downregulation of substance P-mediated
neurokinin 1 receptor
Duy-Khanh Dang1†, Eun-Joo Shin1†, Dae-Joong Kim2, Hai-Quyen Tran1, Ji Hoon Jeong3, Choon-Gon Jang4,
Seung-Yeol Nah5, Jung Hwan Jeong6, Jae Kyung Byun7, Sung Kwon Ko8*, Guoying Bing9, Jau-Shyong Hong10
and Hyoung-Chun Kim1*
Abstract
Background: We previously reported that ginsenoside Re (GRe) attenuated against methamphetamine (MA)-induced
neurotoxicity via anti-inflammatory and antioxidant potentials. We also demonstrated that dynorphin possesses
anti-inflammatory and antioxidant potentials against dopaminergic loss, and that balance between dynorphin
and substance P is important for dopaminergic neuroprotection. Thus, we examined whether GRe positively
affects interactive modulation between dynorphin and substance P against MA neurotoxicity in mice.
Methods: We examined changes in dynorphin peptide level, prodynorphin mRNA, and substance P mRNA, substance
P-immunoreactivity, homeostasis in enzymatic antioxidant system, oxidative parameter, microglial activation,
and pro-apoptotic parameter after a neurotoxic dose of MA to clarify the effects of GRe, prodynorphin
knockout, pharmacological inhibition of κ-opioid receptor (i.e., nor-binaltorphimine), or neurokinin 1 (NK1)
receptor (i.e., L-733,060) against MA insult in mice.
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Results: GRe attenuated MA-induced decreases in dynorphin level, prodynorphin mRNA expression in the striatum of
wild-type (WT) mice. Prodynorphin knockout potentiated MA-induced dopaminergic toxicity in mice. The imbalance of
enzymatic antioxidant system, oxidative burdens, microgliosis, and pro-apoptotic changes led to the dopaminergic
neurotoxicity. Neuroprotective effects of GRe were more pronounced in prodynorphin knockout than in WT mice.
Nor-binaltorphimine, a κ-opioid receptor antagonist, counteracted against protective effects of GRe. In addition,
we found that GRe significantly attenuated MA-induced increases in substance P-immunoreactivity and substance
P mRNA expression in the substantia nigra. These increases were more evident in prodynorphin knockout than in
WT mice. Although, we observed that substance P-immunoreactivity was co-localized in NeuN-immunreactive
neurons, GFAP-immunoreactive astrocytes, and Iba-1-immunoreactive microglia. NK1 receptor antagonist L-733,060 or
GRe selectively inhibited microgliosis induced by MA. Furthermore, L-733,060 did not show any additive effects against
GRe-mediated protective activity (i.e., antioxidant, antimicroglial, and antiapoptotic effects), indicating that NK1 receptor
is one of the molecular targets of GRe.
Conclusions: Our results suggest that GRe protects MA-induced dopaminergic neurotoxicity via upregulatgion of
dynorphin-mediated κ-opioid receptor and downregulation of substance P-mediated NK1 R.
Keywords: Methamphetamine, Dynorphin, κ-opioid receptor, Microglia, Neurokinin 1 receptor
Background
Dynorphin is an endogenous opioid peptide that is
widely distributed in various tissues. Numerous studies
have suggested the involvement of dynorphin in the
pathogenesis of Parkinson’s disease (PD). Earlier studies
reported that reduced mRNA levels of prodynorphin
were observed in the substantia nigra (SN) in postmor-
tem brain specimens of Parkinsonian patients and ani-
mal models of PD [1, 2]. We reported that endogenous
dynorphin attenuates dopaminergic neurotoxicity in-
duced by 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine
(MPTP) or methamphetamine (MA) [3], and that gen-
etic depletion of dynorphin potentiated induction of
pro-inflammatory microglia of M1 phenotype (CD16,
CD32, and CD86) [3].
Substance P is a potent pro-inflammatory neuropep-
tide with high concentrations in the SN [4, 5]. Previous
reports have demonstrated that substance P receptor
(neurokinin-1 receptor) antagonists prevented MA-
induced loss of neurochemical markers of toxicity such
as tyrosine hydroxylase, dopamine transporters, and
tissue dopamine content in the striatum [6, 7]. Hong
and colleagues [8–14] demonstrated the pathogenic role
of microglia-induced neuroinflammation in multiple
neurodegenerative disorders, including PD. Substance P
is capable of stimulating microglial activation to produce
superoxide and pro-inflammatory cytokines, thereby
exacerbating dopaminergic neurodegeneration [13, 14].
We recently demonstrated that substance P might
account for the increased density of microglia in the SN
through chemotaxic recruitment via a novel NK1-NOX2
axis-mediated pathway [15].
Evidence has been reported which suggests the exist-
ence of a dopaminergic influence on the substance P
striatonigral neurons [4, 16–19]. After chronic admin-
istration of the antipsychotic haloperidol, a potent
dopamine receptor antagonist, nigral substance P-like
immunoreactivity (SP-IR) was reduced substantially
[20–22]. The enhancement of dopamine activity with
repeated administrations of the indirect dopamine
agonist methamphetamine (MA) causes elevations of
SP-IR in several structures associated with the basal
ganglia including SN [16]. This MA effect was
blocked by concurrent administration of haloperidol,
suggesting that the action of the drug on the striato-
nigral substance P neurons is mediated through the
dopamine system [16]. Importantly, Block et al. [23]
found that dynorphin inhibited substance P-induced
dopaminergic neurotoxicity in vivo, suggesting the
balance between dynorphin and substance P is essen-
tial for dopaminergic regulation.
Ginsenoside Re (GRe), a potential ginsenoside from
Panax ginseng, exhibited different pharmacological
activities via multiple mechanisms both in vivo and in vitro
[24–29]. We reported that GRe rescues MA-induced
dopaminergic degeneration and pro-inflammatory changes
(i.e., activation of microglia) in vivo by inhibition of protein
kinase Cδ [30]. Interestingly, our pilot study showed that
GRe attenuated MA-induced decrease in prodynorphin
mRNA expression in the striatum of wild-type mice [31].
To extend our knowledge, we investigated whether
GRe requires dynorphin induction for protecting MA-
induced dopaminergic toxicity. In addition, we also
asked whether GRe modulates interaction between
dynorphin/κ-opioid receptor and substance P/neuroki-
nin 1 (NK1) receptor against MA toxicity. Here, we pro-
posed that GRe-mediated neuroprotective effects in vivo
against MA-induced dopaminergic toxicity require
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interactive modulation between dynorphin and sub-
stance P via upregulation of κ-opioid receptor and
downregulation of NK1 receptor.
Methods
Animals
All animals were treated in accordance with the
National Institutes of Health (NIH) Guide for the
Humane Care and Use of Laboratory Animals (NIH
Publication No. 85-23, 1985; grants.nih.gov/grants/
olaw/references/PHSPolicyLabAnimals.pdf ). The present
study was performed in accordance with the Institute for
Laboratory Research (ILAR) Guidelines for the Care and
Use of Laboratory Animals. Mice were maintained under a
12-h light/12-h dark cycle and fed ad libitum. They were
adapted to these conditions for 2 weeks prior to the
experiment.
The prodynorphin knockout (DYN KO) mice were ori-
ginally obtained by targeted deletion of the coding exons of
the prodynorphin gene [32]. We used this animal model in
our previous studies [33, 34]. The DYN KO strain used in
the present study was backcrossed at least nine times to the
C57BL/6 background. Prior to weaning, tail specimens
were collected from each animal, and DNA was extracted
to confirm the presence of the prodynorphin gene locus by
polymerase chain reaction (PCR) using primer pairs specific
for each genotype [32–34]. Primers to detect WT alleles at
the prodynorphin gene locus were 5′-CAGGACCTGGT
GCCGCCCTCAGAG-3′ and 5′-CGCTTCTGGTTGTCC
CACTTCAGC-3′; primers specific for the deletion were
5′-ATCCAGGAAACCAGCAGCGGCTAT-3′ and 5′-ATT
CAGACACATCCCACATAAGGACA-3′. The products
were amplified in a GeneAmp PCR System 9700 (Applied
Biosystems, Foster City, CA, USA) using the following PCR
parameters: an initial denaturation at 94 °C for 5 min, and
then 30 cycles of 94 °C for 30 s, 65 °C for 30 s, 72 °C for
30 s, and 72 °C for 5 min followed by electrophoresis on
1% agarose gels with ethidium bromide and photography
under ultraviolet (UV) light.
Drug treatment
Mice were treated with a single dose of MA (35 mg/kg,
i.p.) or saline, and sacrificed 1 h, 3 h, 6 h, 12 h, 1 day,
and 3 days after MA treatment to examine prodynorphin
and substance P mRNA expressions, ROS formation, and
HNE and protein carbonyl levels. High-performance li-
quid chromatography grade GRe with greater than 99%
purity was provided by Dr. Sung Kwon Ko [35, 36]. GRe
(20 mg/kg, i.p., twice a day) was given 5 days before and
1 day after MA injection. On the day of MA injection,
GRe was administered at 2 h before and 10 h after MA in-
jection. The dose of GRe was determined based on previ-
ous study [30]. Nor-binaltorphimine (Nor-B; κ-opioid
receptor antagonist; Tocris Bioscience, Ellisville, MO,
USA) was dissolved in sterile saline. Nor-B (3 or 6 mg/kg,
i.p.) was given 3 h and 1.5 h before MA injection. The
dose of Nor-B was determined based on previous study
[34]. L-733,060 (NK1 receptor antagonist; Tocris Bio-
science) was dissolved in sterile saline. L-733,060 (5 or
10 mg/kg, i.p.) was given 1 h before MA injection. The
dose of L-733,060 was determined based on previous
study [37].
Dynorphin quantification
For sample preparation, brains were removed and placed
into ice-cold oxygenated artificial cerebrospinal fluid
(aCSF) for approximately 1 min before slicing. The dor-
sal striatum, NAc, and ventral midbrain were free-hand
dissected from 400-μm-thick slices of brain tissue pre-
pared using a vibrating tissue slicer. Tissue samples were
placed in individual eppendorf tubes, flash-frozen in
liquid nitrogen, and stored at − 80 °C until further use.
All tissues were homogenized in RIPA buffer [150 mM
NaCl, 1.0% Triton-X-100, 0.5% Sodium Deoxycholate,
0.1% Sodium Dodecyl Sulfate (SDS), 50 mM Trizma
Base, pH 8.0] and centrifuged at 12,000×g for 30 min.
The pellet was discarded and supernatant used in the
enzyme-linked immunosorbant assay (ELISA). Protein
was measured using the BCA protein assay reagent
(Thermo Scientific, Rockford, IL, USA).
For enzyme-linked immunosorbant assay, a commer-
cially available mouse-dynorphin ELISA kit (MBS727820;
MyBioSource, Inc., San Diego, CA, USA) was utilized to
determine the concentration of dynorphin in the tissue
samples from WT mice. Briefly, standards and samples
(5 μg protein/sample) were pipetted in duplicate into the
96-well plate provided. All reagents were added to wells,
and the plate was washed and incubated according to kit
instructions. The optical density of the samples was read
within 4 min of the final incubation at 450 nm using a mi-
croplate reader (Molecular Devices Inc., Sunnyvale, CA,
USA) [38].
Tissue preparation for enzyme activity assays
Dorsal striatum, nucleus accumbens (NAc), and ventral
midbrain were homogenized in 50 mM potassium phos-
phate buffer (pH 7.0) and centrifuged at 13,000 × g for
20 min. The resulting supernatant was used to measure
the activities of glutathione peroxidase (GPx) and cata-
lase. Additional dorsal striatum, NAc, and ventral mid-
brain were homogenized in 50 mM potassium
phosphate buffer (pH 7.8) and were centrifuged at
13,000 × g for 20 min. The resulting supernatant was
used to measure the activities of superoxide dismutase
(SOD) [30].
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Determination of SOD activity
SOD activity was determined on the basis of inhibition
of superoxide-dependent reactions as described previ-
ously [30] The reaction mixture contained 70 mM po-
tassium phosphate buffer (pH 7.8), 30 μM cytochrome c,
150 μM xanthine, and tissue extract in phosphate buffer
diluted tenfold with PBS in a final volume of 3 mL. The
reaction was initiated by adding 10 μL of 50 units
xanthine oxidase, and the change in absorbance at
550 nm was recorded. One unit of SOD was defined as
the quantity required inhibiting the rate of cytochrome c
reduction by 50%. For estimating total SOD, 10 μM
potassium cyanide (KCN) was added to the medium to
inhibit cytochrome oxidase activity.
Determination of catalase activity
Catalase activity was determined by the rate of hydrogen
peroxide absorbance decrease at 240 nm [30]. The reac-
tion mixture contained 50 mM potassium phosphate buf-
fer (pH 7.0) and an aliquot of the sample. The reaction
started with adding hydrogen peroxide (final concentra-
tion of 10 mM), and absorbance was monitored at 25 °C
for 5 min. Catalase from bovine liver (Sigma-Aldrich, St.
Louis, MO, USA) was used as a standard.
Determination of glutathione peroxidase (GPx) activity
GPx activity was analyzed by a spectrophotometric assay
described by Shin et al. [30], using 2.0 mM reduced
glutathione and 0.25 mM cumene hydroperoxide as sub-
strates. The reaction rate at 340 nm was determined
using the NADPH extinction coefficient (6.22 mM− 1
cm− 1). GPx activity was expressed as nanomole NADPH
oxidized per minute per milligram protein at 25 °C. Pro-
tein was measured using the BCA protein assay reagent,
and bovine serum albumin was used as a standard.
Western blot analysis
Striatal tissues were lysed in buffer containing a 200 mM
Tris–HCl (pH 6.8), 1% SDS, 5 mM ethylene glycol-bis
(2-aminoethyl ether)-N, N, N′, N′-tetraacetic acid
(EGTA), 5 mM EDTA, 10% glycerol, 1 × phosphatase in-
hibitor cocktail I (Sigma-Aldrich, St. Louis, MO, USA),
and 1 × protease inhibitor cocktail (Sigma-Aldrich). Lys-
ate was centrifuged at 12,000×g for 30 min, and the
supernatant fraction was utilized for western blot ana-
lysis as described previously [30, 39]. Proteins (20 μg/
lane) were separated by 8 or 10% SDS-PAGE, and trans-
ferred onto PVDF membranes. Following transfer, the
membranes were preincubated with 5% non-fat milk for
30 min and were incubated overnight at 4 °C with
primary antibody against NeuN (1:200; EMD Millipore,
Temecular, MA, USA), GFAP (1:500; Santa Cruz
Biotechnology, Santa Cruz, CA, USA), Iba-1 (1:500;
Abcam, Cambridge, MA, USA), Bax (1:1000; Santa Cruz
Biotechnology), cleaved caspase-3 (1:1000; Cell Signaling
Technology, Inc., Danvers, MA, USA), caspase-3 (1:1000;
Cell Signaling Technology, Inc.), Bcl-2 (1:1000; Santa Cruz
Biotechnology), TH [1:5000; Chemicon (EMD Millipore)],
or β-actin (1:50000; Sigma-Aldrich). Membranes were then
incubated with HRP-conjugated secondary anti-rabbit IgG
(1:1000, GE Healthcare, Piscataway, NJ, USA), anti-mouse
IgG (1:1000, Sigma-Aldrich), or anti-goat IgG (1:1000,
Sigma-Aldrich) for 2 h. Subsequent visualization was con-
ducted using an enhanced chemiluminescence system
(ECL plus®, GE Healthcare, Arlington Heights, IL, USA).
Relative intensities of the bands were quantified by Photo-
Capt MW (version 10.01 for Windows; Vilber Lourmat,
Marne la Vallée, France) and then normalized to the inten-
sity of β-actin [30].
Immunocytochemistry
Immunocytochemistry was performed as described pre-
viously [30]. Mice were perfused transcardially with
50 mL of ice-cold PBS (10 mL/10 g body weight)
followed by 4% paraformaldehyde (20 mL/10 g body
weight). Brains were removed and stored in 4% parafor-
maldehyde overnight. A series of every sixth section
(35 μm thickness, 210 μm apart) from striatum was
selected and subjected to immunocytochemistry. Sec-
tions were blocked with PBS containing 0.3% hydrogen
peroxide for 30 min and then incubated in PBS contain-
ing 0.4% Triton X-100 and 1% normal serum for 20 min.
After a 48-h incubation with primary antibody against
TH [1:500; Chemicon (EMD Millipore)], Iba-1 (1:500,
Wako Pure Chemical Industries, Chuo-ku, Osaka,
Japan), or substance P (1:500, a kind gift from Dr. Jau-
Shyong Hong, National Institute of Environmental
Health Sciences, USA; this antibody has been described
elsewhere [15]). Sections were incubated with the bio-
tinylated secondary antibody (1:1000; Vector Laborator-
ies, Burlingame, CA, USA) for 1 h. The sections were
then immersed in a solution containing avidin–biotin
peroxidase complex (Vector Laboratories) for 1 h, and
3,3′-diaminobenzidine was utilized as the chromogen.
Digital images were acquired under an upright micro-
scope (BX51; Olympus, Tokyo, Japan) using an attached
digital microscope camera (DP72; Olympus) and an
IBM-compatible PC.
ImageJ software, version 1.47 (National Institutes of
Health, Bethesda, MD, USA) was employed to measure
the immunoreactivities of TH and Iba-1 in the striatum,
or substance P in the SN as described previously [3, 15,
40, 41]. Briefly, images were subjected to background
subtraction to correct for uneven background. The en-
tire striatal region (for TH-immunoreactivity) or the
rectangular region (350 μm× 260 μm, w × h, for Iba-1-
or substance P-immunoreactivity) was drawn as the re-
gion of interest (ROI). Hue, saturation, and brightness
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threshold values were set in the “Adjust Color Thresh-
old” dialog box to select the immunoreactive area, and
then the mean density was measured.
Double-labeled immunocytochemistry
Brain sections of 5 μm thickness obtained from wild-
type (B6) mice were placed on the same slide and proc-
essed for immunostaining. Tissues were adhered on
poly-L-lysine-precoated coverslips, were fixed in PBS-4%
para-formaldehyde (PFA), and were permeabilized with
0.1% Triton X-100 in PBS for 15 min. After saturation
with PBS-1% BSA, tissues were incubated for 40 min
with the primary antibody and were incubated for
40 min with the secondary antibody as follows: primary
antisera were as follows: rabbit anti-substance P ([15];
diluted 1:100), mouse anti-NeuN (1:100, Chemicon),
goat anti-GFAP (1:100, Abcam), and mouse anti-Iba1
(1:100, Abcam). Secondary antibodies were goat anti-
mouse IgG H&L (Alexa Fluor® 568; 1:100, Invitrogen,
Carlsbad, CA, USA), goat anti-rabbit IgG H&L (FITC;
1:500, Abcam), and donkey anti-goat IgG H&L (Alexa
Fluor® 546; 1:200, Invitrogen). Images of samples were
recorded using an FV1000 confocal microscope
(Olympus). To minimize bleed-through, each signal in
double- or triple-stained samples was imaged sequen-
tially. Images were processed in accordance with the
Guidelines for Proper Digital Image Handling using
ImageJ and/or Adobe Photoshop CS3 (Adobe, San
Jose, CA, USA).
Dissection of substantia nigra (SN)
Brains were rapidly removed and cut into 1 mm coronal
sections on ice. The SN was punched using a fine Pas-
teur pipette. The SN was then easily identified and freely
dissected. The total time for isolation of the SN was less
than 3 min. The tissues were stored at − 70 °C until ana-
lysis [42–44].
Reverse transcription and polymerase chain reaction
(RT-PCR)
Expression of prodynorphin and substance P was
assessed using quantitative RT–PCR to analyze mRNA
levels, as described previously [45]. Total RNA was iso-
lated from striatal or nigral tissues using an RNeasy Mini
Kit (Qiagen, Valencia, CA, USA) according to the manu-
facturer’s instructions. Reverse transcription reactions
were carried out using the RNA to cDNA EcoDry
Premix (Clontech, Palo Alto, CA, USA) with a 1-h incu-
bation at 42 °C. PCR amplification was performed using
25 cycles of denaturation at 94 °C for 1 min, annealing
at 60 °C for 2 min, and extension at 72 °C for 1 min.
The primer sequences and predicted product sizes for
the amplified genes were as follows: prodynorphin
(510 bp), 5′-CAG GAC CTG GTG CCG CCC TCA
GAG-3′ (forward) and 5′-CGC TTC TGG TTG TCC
CAC TTC AGC-3′ (reverse); substance P (194 bp), 5′-
AAG CCT CAG CAG TTC TTT GGA T-3′ (forward)
and 5′-GTT CTG CAT CGC GCT TCT TTC-3′ (re-
verse); and glyceraldehyde 3-phosphate dehydrogenase
(GAPDH; 450 bp), 5′-ACC ACA GTC CAT GCC ATC-
3′ (forward) and 5′-TCC ACC ACC CTG TTG CTG
TA-3′ (reverse). PCR products were separated on 2%
agarose gels containing ethidium bromide and visualized
under ultraviolet light. Quantitative analysis of RNA was
performed using PhotoCapt MW (version 10.01 for
Windows; Vilber Lourmat).
Synaptosome preparation
Striatal tissue was homogenized in 10 volume of ice-cold
0.32 mol/L sucrose and centrifuged at low speed (800×g,
12 min, 4 °C). This resulted in supernatant (S1) that was
removed and centrifuged at high speed (22,000×g,
20 min, 4 °C) in order to yield pelleted synaptosomes.
An aliquot of the re-suspended (P2) synaptosomal frac-
tion was used for determination of ROS formation [39].
Determination of ROS formation
ROS formation in the synaptosome was assessed by
measuring the conversion from 2′,7′-dichlorofluorescin
diacetate (DCFH-DA) to dichlorofluorescin (DCF) [46].
Synaptosomal fractions were added to a tube containing
2 mL of phosphate-buffered saline (PBS) with 10 nmol
of DCFH-DA, dissolved in methanol. The mixture was
incubated at 37 °C for 3 h, and then fluorescence was
measured at 480 nm excitation and 525 nm emission.
DCF was used as a standard.
Determination of 4-hydroxynonenal (HNE)
The amount of lipid peroxidation was determined by
measuring the level of 4-hydroxynonenal (HNE) using
the OxiSelect™ HNE adduct ELISA kit (Cell Biolabs, Inc.,
San Diego, CA, USA) according to the manufacturer’s
instructions. 100 μL of striatal homogenate at a protein
concentration of 10 μg/mL was incubated in a 96-well
protein binding plate at 4 °C overnight. After protein ad-
sorption, HNE adducts in each well were labeled with
HNE antibody followed by HRP-conjugated secondary
antibody. Colorimetric development was then performed
with substrate solution. Absorbance was recorded at
450 nm using a microplate reader (Molecular Devices
Inc.), and an amount of HNE adduct in each sample was
calculated from the standard curve of HNE-BSA [30].
Determination of protein carbonyl
The extent of protein oxidation was assessed by measur-
ing the content of protein carbonyl groups, which was
determined spectrophotometrically with the 2,4-dinitro-
phenylhydrazine (DNPH)-labeling procedure [30] as
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described by Oliver [47]. The results are expressed as
nmol of DNPH incorporated/mg protein based on the
extinction coefficient for aliphatic hydrazones of 21 mM
− 1 cm− 1. Protein was measured using the BCA protein
assay reagent (Thermo Scientific, Rockford, IL, USA).
Measurement of dopamine (DA) and its metabolites
Mice were sacrificed by cervical dislocation, and the
brains were removed. The dorsal striatum, NAc, and
ventral midbrain were dissected as above, were imme-
diately frozen in liquid nitrogen, and were stored at
− 70 °C before assays. Tissues were weighed, ultraso-
nicated in 10% perchloric acid, and centrifuged at
20,000×g for 10 min. The levels of DA and its metab-
olites DOPAC and HVA were determined by HPLC
coupled with an electrochemical detector, as described
previously [3, 30, 43]. Supernatant aliquots (20 μL)
were injected into an HPLC equipped with a C18 col-
umn with 3 μm particle size (Waters). The mobile
phase was comprised of 26 mL of acetonitrile, 21 mL
of tetrahydrofuran, and 960 mL of 0.15 M mono-
chloroacetic acid (pH 3.0) containing 50 mg/L of
EDTA and 200 mg/mL of sodium octyl sulfate. The
amount of DA was determined by comparison of
peak areas of tissue samples with standard and was
expressed in ng/g of wet tissue.
Statistical analyses
Data were analyzed using IBM SPSS ver. 21.0 (IBM,
Chicago, IL, USA). One-way analysis of variance
(ANOVA) or two-way ANOVA was employed for statis-
tical analyses. Post-hoc Fisher’s least significant differ-
ence (LSD) pairwise comparison tests were then
conducted. p values < 0.05 were considered to be
significant.
Results
MA-induced changes in dynorphin level, prodynorphin
mRNA, and substance P mRNA expression in the dorsal
striatum of wild-type (WT) mice
We demonstrated a protective role of dynorphin in the
modulation of dopaminergic system [3]. As shown in
Fig. 1, we conducted a time-course study to elucidate
changes in dynorphin level prodynorphin mRNA and
substance P mRNA. Dynorphin level was significantly
decreased 3 h (p < 0.05), 6 h (p < 0.01), 12 h (p < 0.05),
and 1 day (p < 0.05) after a toxic dose of MA (Fig. 1a).
The most pronounced decrease in dynorphin level was
noted 6 h post-MA. Importantly, MA-induced decrease in
dynorphin level in the dorsal striatum was most evident
among nucleus accumbens, ventral midbrain, and dorsal
striatum (please refer to Additional file 1: Figure S1).
Interestingly, MA treatment did not change prodynorphin
mRNA expression 3 and 6 h later, indicating that
Fig. 1 MA-induced changes in dynorphin level, prodynorphin
mRNA, and substance P mRNA expression. Changes in dynorphin
level (a), prodynorphin (b), and substance P (c) mRNA expression
in the dorsal striatum of wild-type mice. Sal = saline, MA =
methamphetamine 35 mg/kg, i.p. Each value is the mean ± SEM
of six animals (one-way ANOVA followed by Fisher’s LSD
pairwise comparisons)
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compensatory induction to significant decreases in dynor-
phin level. MA-induced significant decreases in prodynor-
phin mRNA expression was observed 12 h (p < 0.05) and
1 day (p < 0.01) later (Fig. 1b). This decrease was more
pronounced in 1 day post-MA (p < 0.05) than in 12 h
post-MA (Fig. 1b). As presented in Fig. 1c, a significant
increase (p < 0.01) in substance P mRNA expression was
noted 1 day after MA of WT mice. Therefore, we have fo-
cused on 1 day time-point for further study.
Effects of genetic depletion of prodynorphin on MA-
induced changes in superoxide dismutase (SOD), catalase,
and glutathione peroxidase (GPx) activity in the dorsal
striatum, nucleus accumbens (NAc), and ventral midbrain
in mice
As shown in Table 1A–C, MA treatment initially in-
creased (p < 0.05 vs. saline) SOD activity and decreased
GPx activity 3 h later in the dorsal striatum (p < 0.05 vs.
saline), NAc (p < 0.05 vs. saline) and ventral midbrain
(p < 0.05 vs. saline) of WT mice. MA treatment initially
increased (p < 0.05) catalase activity 6 h later in the
ventral midbrain, however, initially increased catalase
activity 3 h later in the dorsal striatum (p < 0.05 vs.
saline) and NAc (p < 0.05 vs. saline) of WT mice. All of
these changes returned near saline level 3 days later.
These changes appeared to be more pronounced in
dorsal striatum than in NAc or ventral midbrain.
In addition, MA treatment exhibited in a sustained
increases in SOD activity 6 h (dorsal striatum, NAc, or
ventral midbrain; p < 0.01 vs. corresponding saline), 12 h
(dorsal striatum or ventral midbrain; p < 0.01 vs. corre-
sponding saline. NAc; p < 0.05 vs. corresponding saline),
and 1 day (dorsal striatum or ventral midbrain; p < 0.01
vs. corresponding saline. NAc; p < 0.05 vs. corresponding
Table 1 Effect of genetic depletion of prodynorphin on MA-induced changes in activity in enzymatic antioxidants
A
SOD (units/mg protein) Saline MA
1 h 3 h 6 h 12 h 1 day 3 days
Dorsal striatum WT 6.1 ± 0.6 7.5 ± 0.5† 8.4 ± 0.7*’‡ 12 ± 0.4**‡ 11.1 ± 0.8**‡ 10.0 ± 0.3**‡ 6.5 ± 0.4
DYN KO 6.0 ± 0.3 – – 15.5 ± 0.7**,# – 12.9 ± 0.3**,# –
NAc WT 5.0 ± 0.3 5.6 ± 0.5 6.7 ± 0.3* 6.3 ± 0.3** 7.1 ± 0.6* 6.8 ± 0.4* 5.7 ± 0.4
DYN KO 4.8 ± 0.4 – – 11.1 ± 0.5**,# – 9.1 ± 0.5**,# –
Ventral midbrain WT 5.8 ± 0.4 6.5 ± 0.4 7.4 ± 0.3*,& 9.7 ± 0.6**,& 8.4 ± 0.5**,& 7.9 ± 0.4**,& 6.3 ± 0.5
DYN KO 5.9 ± 0.6 – – 12 ± 0.6**,# – 10.2 + 0.4 –
B
Catalase (units/mg protein) Saline MA
1 h 3 h 6 h 12 h 1 day 3 days
Dorsal striatum WT 1.7 ± 0.09 2.0 ± 0.16† 2.1 ± 0.07*,† 2.4 ± 0.14**,† 2.6 ± 0.19**,‡ 2.5 ± 0.13**,‡ 1.9 ± 0.09
DYN KO 1.6 ± 0.08 – – 2.4 ± 0.06** – 2.2 ± 0.08* –
NAc WT 1.4 ± 0.06& 1.5 ± 0.1 1.6 ± 0.08* 1.7 ± 0.08 1.9 ± 0.06** 1.8 ± 0.11* 1.6 ± 0.07*
DYN KO 1.2 ± 0.05 – – 1.8 ± 0.08* – 1.6 ± 0.09* –
Ventral midbrain WT 1.6 ± 0.09 1.7 ± 0.32 1.8 ± 0.12 1.9 ± 0.09* 2.2 ± 0.13**,& 2.1 ± 0.11**,& 1.8 ± 0.09
DYN KO 1.3 ± 0.07 – – 2 ± 0.09* – 1.8 ± 0.09* –
C
GPx (nmole NADPH/min/mg protein) Saline MA
1 h 3 h 6 h 12 h 1 day 3 days
Dorsal striatum WT 9.9 + 0.3 8.5 ± 0.8 7.4 ± 0.4* 4.9 ± 0.5**,† 5.4 ± 0.3**,† 5.6 ± 0.4**,† 8.4 ± 0.6
DYN KO 9.3 ± 0.5 – – 3.9 ± 0.5**,# – 5.3 ± 0.4**,# –
NAc WT 8.7 ± 0.4 8.3 ± 0.3 7.3 ± 0.3* 6.3 ± 0.3** 6.7 ± 0.2** 7.1 ± 0.5** 8.3 ± 0.2
DYN KO 8.2 ± 0.4 – – 4.9 ± 0.3**,# – 6.1 ± 0.4**,# –
Ventral midbrain WT 9.2 ± 0.6 8.7 ± 0.3 7.8 ± 0.5* 6.7 ± 0.3** 6.7 ± 0.5** 7.0 ± 0.4** 8.6 ± 0.3
DYN KO 8.9 ± 0.4 – – 5.1 ± 0.5**,# – 6.3 ± 0.5**,# –
SOD superoxide dismutase, GPx glutathione peroxidase, Sal saline, MA methamphetamine 35 mg/kg, i.p, WT wild-type mice, DYN KO prodynorphin knockout mice.
Each value is the mean ± SEM of six animals [two-way ANOVA (time points × brain regions) followed by Fisher’s LSD pairwise comparisons. Additional two-way
ANOVA (time points × gene) with Fisher’s LSD pairwise comparisons was done to examine the effect of DYN KO 6 h and 1 day after MA]. *p < 0.05,**p < 0.01 vs.
corresponding Saline.#p < 0.05,##p < 0.01 vs. corresponding MA/WT. †p < 0.05, ‡p < 0.01 vs. corresponding NAc or ventral midbrain. &p < 0.05 vs. corresponding NAc
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saline) later in WT mice. SOD activity of dorsal striatum
(SOD activity 1 h, 3 h, 12 h, or 1 day post-MA; p < 0.05
vs. corresponding SOD activity of NAc or ventral mid-
brain) was significantly higher than that of NAc or ven-
tral midbrain. SOD activity of ventral midbrain (3 h, 6 h,
12 h, or 1 day post-MA; p < 0.05 vs. corresponding SOD
activity of NAc) was higher than that of NAc (Table 1A).
We examined whether genetic depletion of prodynor-
phin affects enzymatic antioxidants activity induced by
MA. Because SOD and GPx activities were significantly
changed 6 h post-MA and prodynorphin and substance
P mRNA expressions were significantly changed 1 day
post-MA, we focused on 6 h and 1 day post-MA.
Prodynorphin knockout significantly potentiated
increases in SOD activity 6 h (dorsal striatum, NAc, or
ventral midbrain; p < 0.05 vs. corresponding brain region
of WT mice) and 1 day (dorsal striatum, NAc, or ventral
midbrain; p < 0.01 vs. corresponding brain region of WT
mice. Dorsal striatum; p < 0.05 vs. corresponding brain
region of prodynorphin knockout mice) after MA treat-
ment in WT mice (Table 1A). Similar to SOD, MA treat-
ment significantly increased catalase activity in WT mice
(Table 1B). However, genetic inhibition of prodynorphin
did not significantly affect catalase activity of dorsal
striatum, NAc, and ventral midbrain of WT mice
(Table 1B).
In contrast, treatment with MA resulted in signifi-
cant decreases in GPx activity 3 h (dorsal striatum,
NAc, or ventral midbrain; p < 0.05 vs. corresponding
saline), 6 h (dorsal striatum, NAc, or ventral mid-
brain; p < 0.01 vs. corresponding saline), 12 h (dorsal
striatum, NAc, or ventral midbrain; p < 0.01 vs. corre-
sponding saline), and 1 day (dorsal striatum, NAc, or
ventral midbrain; p < 0.01 vs. corresponding saline)
later in WT mice. GPx activity of dorsal striatum
(6 h, 12 h, or 1 day post-MA; p < 0.05 vs. correspond-
ing GPx activity of NAc or ventral midbrain) was sig-
nificantly lower than that of NAc and ventral
midbrain of MA-treated WT mice (Table 1C). Prody-
norphin knockout significantly decreased (dorsal
striatum, NAc, or ventral midbrain; p < 0.05 vs. corre-
sponding brain region of WT mice) GPx activity 6 h
and 1 day post-MA treatment in WT mice
(Table 1C).
MA-induced changes oxidative burdens [i.e., reactive
oxidative stress (ROS), 4-hydroxynonenal (HNE), and
protein carbonyl level] in the dorsal striatum of wild-type
(WT) mice
It is well-known that oxidative stress is a key element
in MA neurotoxicity [48]. Because dorsal striatum
was the most sensitive to MA-induced changes in en-
zymatic antioxidant as shown in Fig. 2, we focused
on dorsal striatum. In our study, parameters of
Fig. 2 MA-induced changes oxidative burdens in the dorsal striatum
of wild-type (WT) mice. Sal = saline, MA =methamphetamine 35 mg/
kg, i.p., ROS = reactive oxygen species, HNE = 4-hydroxynonenal. Each
value is the mean ± SEM of six animals (one-way ANOVA followed
by Fisher’s LSD pairwise comparisons)
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oxidative stress (i.e., ROS, HNE, and protein carbonyl
level) were significantly elevated after MA (ROS: 1 h,
p < 0.05; 3 h, p < 0.01; 6 h, p < 0.01; 12 h, p < 0.05;
1 day, p < 0.05. HNE: 1 h, p < 0.05; 3 h, p < 0.01; 6 h,
p < 0.01; 12 h, p < 0.01; 1 day, p < 0.05. Protein car-
bonyl: 1 h, p < 0.05; 3 h, p < 0.01; 6 h, p < 0.05; 12 h,
p < 0.05; 1 day, p < 0.05), which consistently reached
the highest level 3 h post-MA (Fig. 3a–c).
Effects of κ-opioid receptor antagonist nor-binaltorphimine
(Nor-B) on the pharmacological activity of ginsenoside Re
(GRe) against MA-induced increase in substance P level in
WT and prodynorphin KO mice
As shown in Fig. 3a, Nor-B was treated two times before
MA administration, and mice received GRe (20 mg/kg,
i.p.) for 6 days (5 days before and 1 day after MA). As
presented in Fig. 3b, MA-induced decrease (p < 0.01 vs.
Sal/Sal) in prodynorphin mRNA expression was signifi-
cantly attenuated (p < 0.05) by treatment with GRe. A
little substance P-immunoreactivity was observed in the
striatum of mice with or without MA (Additional file 1:
Figure S2). However, there was a significant induction of
substance P-immunoreactivity in the SN of WT mice
1 d post-MA (p < 0.01) (Additional file 1: Figure S2).
GRe treatment attenuated MA-induced increases in the
substance P-immunoreactivity (p < 0.05) and substance
P mRNA expression (p < 0.05) in the SN of mice
(Fig. 3c, d). MA-induced increases in substance P
levels were more prominent in prodynorphin KO than
WT mice (p < 0.05). Nor-B (6 mg/kg, i.p.) significantly
counteracted GRe-mediated attenuation against sub-
stance P-immunoreactivity (p < 0.05) or substance P
mRNA expression (p < 0.05) induced by MA in prody-
norphin KO mice (Fig. 3c, d), indicating that GRe
requires upregulation of κ-opioid receptor modulation
for exerting antioxidant potential.
For more details on Nor-B activity against
GRe-mediated effects in WT mice, please refer to
Additional file 1: Figure S3.
Effects of neurokinin 1 (NK1) receptor antagonist L-733,060
on κ-opioid receptor antagonist, nor-binaltorphimine
(Nor-B)-mediated pharmacological activity in response to
antioxidant effects of ginsenoside Re (GRe) against MA
insult in the striatum of prodynorphin KO mice
As shown in Fig. 4, oxidative stress (i.e., ROS, HNE, and
protein carbonyl level) 3 h post-MA was more evident
in prodynorphin KO mice (ROS, HNE, or protein car-
bonyl level: p < 0.05 vs. corresponding WT) than that in
WT mice. Nor-B counteracted (ROS, HNE, or protein
carbonyl level: p < 0.05, respectively) antioxidant effects
of GRe in a dose-related manner. L-733,060 inhibited
Nor-B-mediated counteraction against the antioxidant
effect of GRe in prodynorphin KO mice (p < 0.05). In
addition, L-733,060 itself attenuated against oxidative
stress (ROS, HNE, or protein carbonyl level: p < 0.05, re-
spectively) induced by MA. L-733,060 did not exhibit
any additive effects in response to GRe-mediated anti-
oxidant effect, suggesting that GRe possesses an inter-
active pharmacological activity between κ-opioid
receptor and NK1 receptor.
The effects of Nor-B on GRe-mediated antioxidant po-
tential in WT mice were shown in Additional file 1: Fig-
ure S4.
Substance P-immunoreactivity is expressed in NeuN-
immunoreactive neurons, GFAP-immunoreactive
astrocytes, or Iba-1-immunoreactive microglial cells in the
substantia nigra of WT mice
It was also reported that microglia expresses the substance
P gene and NK1 receptor [49]. In order to determine if
substance P modulates neuron, astrocyte, and microglia in
our experimental system, we conducted double-labeling
immunocytochemistry. Substance P-immunoreactivity
was co-localized in NeuN-, GFAP-, or Iba-1 immunoreac-
tive cells, suggesting that substance P-immunoreactivity is
expressed in neurons, reactive astrocytes, or reactive
microglia after MA treatment (Fig. 5).
Effects of neurokinin 1 (NK1) receptor antagonist, L-733,060
on κ-opioid receptor antagonist, nor-binaltorphimine
(Nor-B)-mediated pharmacological activity in response to
effects of ginsenoside Re (GRe) against changes in NeuN,
GFAP, and Iba-1 expression induced by MA in the striatum
of prodynorphin KO mice
As presented in Fig. 6a, MA treatment significantly
decreased (p < 0.05) NeuN expression in both WT and
prodynorphin KO mice. GRe, L-733,060, or Nor-B did
not significantly alter NeuN expression induced by MA.
In contrast, MA tended to increase GFAP expression
without reaching statistical analysis in WT mice. How-
ever, MA significantly increased (p < 0.05) GFAP expres-
sion in DYN KO mice. MA-induced increase in GFAP
expression was prevented (p < 0.05) by L-733,060, but
not by GRe (Fig. 6b). Importantly, Iba-1 expression
was significantly increased in the striatum 1 day after
MA (p < 0.05). MA-induced increase in Iba-1 expres-
sion was more evident (p < 0.05) in prodynorphin KO
than in WT mice. Either GRe (p < 0.05) or L-733,060
(p < 0.05) significantly attenuated MA-induced in-
crease in Iba-1 expression. Treatment of L-733,060
did not exhibit any additional effects in response to
the pharmacological activity of GRe. Nor-B (6 mg/kg,
i.p.) counteracted (p < 0.05) against GRe-mediated
attenuation in Iba-1 expression. L-733,060 treatment
inhibited (p < 0.05) Nor-B-induced counteraction
(Fig. 6a). This phenomenon consistently paralleled
Iba-1-immunoreactivity (Iba-1-IR), indicating that
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Fig. 3 Role of κ-opioid receptor in GRe-mediated modulation of prodynorphin and substance P. Experimental design for determining whether
κ-opioid receptor is involved in GRe-mediated effects against dopaminergic toxicity induced by MA; mice received Nor-B by two times (3 and 1.5 h)
before MA treatment. Mice received ginsenoside Re twice a day for seven consecutive days (i.e., 5 days before and 1 day after MA) (a). Effect of GRe on
MA-induced decrease in prodynorphin mRNA expression in the striatum of mice (b). Effects of κ-opioid receptor antagonist Nor-B on GRe-mediated
pharmacological activity against MA-induced increases in substance P (SP)-immunoreactivity (c) and substance P mRNA expression (d) in the substantia
nigra (SN) of DYN KO mice. Sal = saline, MA=methamphetamine 35 mg/kg, i.p., GRe = ginsenoside Re 20 mg/kg, i.p., Nor-B = nor-binaltorphimine 3 or
6 mg/kg, i.p., WT =wild-type mice, DYN KO = prodynorphin knockout. Each value is the mean ± SEM of six animals [two-way ANOVA (B) or one-way
ANOVA (C and D) followed by Fisher’s LSD pairwise comparisons]. Scale bar = 100 μm
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western blotting analysis (Fig. 6c) supports immuno-
staining (Fig. 6d). As shown in Additional file 1: Fig-
ure S5, MA-induced Iba-1-immunoreactive microglial
cells were more pronounced in the striatum than in
the SN. For more details on the effects of Nor-B on
the protective activity of GRe against microglial acti-
vation induced by MA in WT mice, please refer to
Additional file 1: Figure S6.
Effects of neurokinin 1 (NK1) receptor antagonist L-
733,060 on κ-opioid receptor antagonist nor-
binaltorphimine (Nor-B)-mediated pharmacological activ-
ity in response to effects of ginsenoside Re (GRe) against
pro-apoptotic changes induced by MA in the striatum of
prodynorphin KO mice
Cadet and colleagues [50] made the first in vivo demon-
stration that a neurotoxic dose of MA causes differential
regulation of several Bcl-2 family genes with two distinct
clustering consisting of upregulation of pro-death and
downregulation of anti-death gene expression. Their re-
sults brought further highlight the role that pro-
apoptotic cell death plays an important role in MA
neurotoxicity [51–57].
As presented in Fig. 7a, b, MA treatment significantly
increased Bax (p < 0.01) and cleaved caspase-3 (p < 0.01)
expression in WT mice. MA-induced Bax and cleaved
caspase-3 expression was more evident (p < 0.05, re-
spectively) in prodynorphin KO mice than in WT. GRe
or L-733,060 attenuated MA-induced increase in Bax (p
< 0.05) and cleaved caspase-3 (p < 0.05) expression in
prodynorphin KO mice. Consistently, MA significantly
decreased (p < 0.01) Bcl-2 expression (Fig. 7c). This de-
crease was more pronounced in prodynorphin KO (p <
0.05) than in WT mice, which was significantly attenu-
ated by treatment with GRe (p < 0.05) or L-733,060 (p <
0.05). L-733,060 did not produce any additional effect
against the anti-apoptotic potential mediated by GRe.
The attenuation by GRe was significantly counter-
acted (p < 0.05) by Nor-B (6 mg/kg, i.p.), which was
subsequently inhibited (p < 0.05) by L-733,060
(10 mg/kg, i.p.).
The effects of Nor-B on the protective activity of GRe
against MA-induced apoptotic changes in WT were pre-
sented in Additional file 1: Figure S7.
Effects of genetic depletion of prodynorphin on MA-
induced changes in dopamine and dopamine turnover
rate in the dorsal striatum, nucleus accumbens (NAc), and
ventral midbrain of mice
As shown in Fig. 8a–c, we investigated whether pro-
dynorphin knockout affects MA-induced dopamin-
ergic impairments in mice. MA-induced significant
decreases in dopamine level was observed in dorsal
striatum (p < 0.01 vs. saline), NAc (p < 0.05 vs. saline),
Fig. 4 Role of κ-opioid receptor and neurokinin 1 receptor in GRe-
mediated antioxidant potentials. Effects of neurokinin 1 receptor antagon-
ist L-733,060 on Nor-B-mediated pharmacological activity in response to
antioxidant effect of GRe against ROS formation (a), HNE (b), and protein
carbonyl (c) levels induced by MA. Sal = saline, MA=methamphetamine
35 mg/kg, i.p., GRe = ginsenoside Re 20 mg/kg, i.p., Nor-B =Nor-binaltor-
phimine 3 or 6 mg/kg, i.p., L733 = L-733,060 5 or 10 mg/kg, i.p., ROS=
reactive oxygen species, HNE = 4-hydroxynonenal, WT =wild type, DYN
KO=prodynorphin knockout. Each value is the mean ± SEM of six animals
(one-way ANOVA followed by Fisher’s LSD pairwise comparisons)
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and ventral midbrain (p < 0.01 vs. saline) in WT mice.
MA-induced dopamine loss was more pronounced
(p < 0.05 vs. WT) than in the dorsal striatum of pro-
dynorphin knockout mice. However, prodynorphin
knockout did not significantly affect MA-induced
dopaminergic loss in NAc and ventral midbrain. Con-
sistently, MA-induced dopamine turnover rate was
significantly increased in dorsal striatum, NAc, and
ventral midbrain in WT and prodynorphin knockout
mice. Dopamine turnover rate was higher in the dor-
sal striatum of MA-treated prodynorphin knockout
(p < 0.05) than WT mice. However, prodynorphin
knockout did not significantly change dopamine turn-
over rate of NAc and ventral midbrain in mice. Thus,
we focused on dorsal striatum for the mechanistic
study on dopaminergic system.
Fig. 5 MA-induced changes in substance P-immunodistribution. Substance P-immunoreactivity was localized in the NeuN-labeled neurons (a),
GFAP-labeled astrocytes (b), and Iba-1-labeled microglial cells (c). Arrow indicates co-localization. Scale bar = 100 μm
Dang et al. Journal of Neuroinflammation  (2018) 15:52 Page 12 of 22
Effects of neurokinin 1 (NK1) receptor antagonist L-733,060
on κ-opioid receptor antagonist nor-binaltorphimine (Nor-B)-
mediated pharmacological activity in response to effects of
ginsenoside Re (GRe) against dopaminergic impairments
induced by MA in the dorsal striatum of prodynorphin
KO mice
MA-induced decrease (p < 0.01) in TH-immunoreactivity
(TH-IR) of WT mice. This decrease was more pro-
nounced (p < 0.05) in prodynorphin KO mice than in WT
mice (Fig. 9a and Additional file 1: Figure S8). This
decrease in prodynorphin KO mice was significantly
protected by treatment with GRe (p < 0.05) or L-
733,060 (p < 0.05). L-733,060 did not exhibit any additive
effects against neuroprotective effects of GRe. Nor-B
(6 mg/kg, i.p.) significantly counteracted (p < 0.01) the
protective effects of GRe. Counteraction by Nor-B was
significantly inhibited (p < 0.01) by L-733,060 (10 mg/kg,
i.p.). Result of TH-IR paralleled that of TH expression and
dopamine level, respectively (Fig. 9b, c). Consistently, in-
crease (p < 0.05) in dopamine turnover rate was more
Fig. 6 Role of κ-opioid and neurokinin 1 receptors in GRe-mediated neuronal, astrocytic, and microglial modulation. Effects of neurokinin
1 receptor antagonist L-733,060 on κ-opioid receptor antagonist Nor-B-mediated pharmacological activity in response to effects of GRe
against the changes in NeuN (a), GFAP (b), Iba-1 expression (c), and Iba-1-immunoreactivity (d) induced by MA in the striatum of DYN
KO mice. Sal = saline, MA =methamphetamine 35 mg/kg, i.p., GRe = ginsenoside Re 20 mg/kg, i.p., Nor-B = Nor-binaltorphimine 3 or 6 mg/
kg, i.p., L733 = L-733,060 5 or 10 mg/kg, i.p., GFAP = glial fibrillary acidic protein, Iba-1 = ionized calcium-binding adapter molecule 1, WT =
wild type, DYN KO = prodynorphin knockout. Each value is the mean ± SEM of six animals (one-way ANOVA followed by Fisher’s LSD pair-
wise comparisons). Scale bar = 100 μm
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pronounced in prodynorphin KO than in WT mice.
Although GRe or L-733,060 attenuated this increase
(p < 0.05), L-733,060 did not show any additional ef-
fects against dopaminergic neuroprotective activity of
GRe. Nor-B treatment significantly counteracted (p < 0.05)
neuroprotective effects of GRe. L-733,060 treatment
inhibited (p < 0.05) against the counteraction induced by
Nor-B (Fig. 9d).
The effects of Nor-B on the protective activity of GRe
against dopaminergic impairments induced by MA in
WT were shown in Additional file 1: Figure S9.
Discussion
Accumulating evidence has suggested that the positive
effects of GRe may be due to its antioxidant and
anti-inflammatory activities [30, 58]. Similarly, we ob-
served that endogenous dynorphin plays a critical role
in protecting dopaminergic neurons through its anti-
inflammatory effects [3]. Here, we found that GRe
modulated positive interaction between dynorphin
and substance P to suppress oxidative stress and pro-
inflammatory responses induced by MA. In line with
previous reports [6, 7], we observed that NK1 recep-
tor antagonism attenuated against MA-induced dopa-
minergic toxicity. However, NK1 receptor antagonist
L-733,060 did not show any additional positive effect
against neuroprotective activity by GRe, indicating
that NK1 receptor is also one of the molecular
pharmacological targets for GRe-mediated neuropro-
tective activity. Our result may be in line with a pre-
vious finding [23] that interaction between dynorphin
and substance P is critical for modulating dopamin-
ergic neurotoxicity. GRe treatment significantly atten-
uated MA-induced oxidative burdens, microglial
activation, pro-apoptotic changes, and dopaminergic
impairments via positive modulation between
dynorphin-mediated κ-opioid receptor and substance
P-mediated NK1 receptor (Fig. 10).
In this study, we selected a neurotoxic model induced
by MA (35 mg/kg, i.p.), because this acute toxic model
efficiently induces neuronal pro-apoptosis in the mouse
striatum [53, 59]. Our recent reports indicated that a
single, high dose of MA selectively induces proapoptosis
Fig. 7 Role of κ-opioid and neurokinin 1 receptors in GRe-mediated
anti-apoptotic potentials. Effects of neurokinin 1 receptor antagonist
L-733,060 on κ-opioid receptor antagonist Nor-B-mediated
pharmacological activity in response to effects of GRe against
the changes in Bax (a), cleaved caspase-3 (b), and Bcl-2 expression (c) in-
duced by MA in the striatum of DYN KO mice. Sal = saline, MA=meth-
amphetamine 35 mg/kg, i.p., GRe = ginsenoside Re 20 mg/kg, i.p., Nor-B
= Nor-binaltorphimine 3 or 6 mg/kg, i.p., L733 = L-733,060 5 or 10 mg/kg,
i.p., WT =wild type, DYN KO= prodynorphin knockout. Each value is the
mean ± SEM of six animals (one-way ANOVA followed by Fisher’s LSD
pairwise comparisons)
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in the striatum of mice [55, 60]. This range of MA dose
also induces the loss of striatal dopamine terminal
markers, such as dopamine transporter, tyrosine hydrox-
ylase, and tissue dopamine content [61–63].
Dynorphin is the major posttranslational product of
the prodynorphin gene and the presumed endogenous
ligand for the κ-opioid receptor [34]. El Daly et al. [64]
found that the systemic administration of a selective κ-
opioid receptor agonist U69593 attenuated reduction in
presynaptic dopamine neuronal function in response to
repeated methamphetamine administration. Consist-
ently, our finding indicated that κ-opioid receptor plays
a protective role in dopaminergic neurodegeneration in-
duced by a toxic dose of MA. κ-opioid receptor
activation attenuates the initiation and long-term
expression of sensitization to the locomotor-activating
effects of cocaine [65–68]. Earlier studies have shown
that κ-opioid receptor agonists modulate dopaminergic
neurotransmission in the SN, neostriatum, and the
mesolimbic system [69–72]. Administration of dynor-
phin (1–13), the postulated endogenous ligand for the
κ-opioid receptor, also attenuated the development of D-
amphetamine-induced behavioral sensitization [73].
Therefore, it is possible that κ-opioid receptor agonist
might be important for positive dopaminergic
modulation.
In this study, treatment with MA resulted in signifi-
cant and constant increases in SOD activity in the dorsal
Fig. 8 Effects of genetic depletion of DYN on MA-induced dopaminergic change. a Effects of dorsal striatum. b Effects of nucleus accumbens. c Effects
of ventral midbrain. Sal = saline, MA =methamphetamine 35 mg/kg, i.p., GRe = ginsenoside Re 20 mg/kg, i.p., Nor-B = Nor-binaltorphimine 3 or 6 mg/
kg, i.p., L733 = L-733,060 5 or 10 mg/kg, i.p., WT =wild type, DYN KO= prodynorphin knockout. Each value is the mean ± SEM of six animals (two-way
ANOVA followed by Fisher’s LSD pairwise comparisons)
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striatum (> ventral midbrain > NAc) of mice, but did
not involve a concomitant increase in GPx activity. In-
creased SOD activity can lead to an accumulation of
H2O2, which in the absence of simultaneous increases in
the activity of GPx, could increase Fenton reactions
leading to the stimulation of ROS and lipid peroxida-
tion/protein oxidation that result in irreversible cellular
damage [74, 75]. In contrast, increased catalase activity
in MA-treated wild-type mice could be an adaptive re-
sponse to higher levels of H2O2 generated by inhibition
of GPx activity, the brain has low-level catalase activity
and only moderate amounts of SOD and GPx [75, 76].
Our observation of increased ROS, and lipid peroxida-
tion/protein oxidation products implies that GPx activ-
ity, rather than increased SOD, modulates these
endpoints. Furthermore, significant elevation of SOD
activity in the early stages of MA insult in mice could be
a response to the enhanced superoxide generated during
MA-induced neurotoxicity [43, 77]. In other words, in-
creased activity of SOD as well as decreased GPx activity
in prodynorphin KO mice may be responsible for
accumulating H2O2 levels, which could activate oxidative
burdens. Therefore, the protective effect against MA-
induced dopaminergic deficits in the presence of GRe
might reflect an upregulation of dynorphin/ κ-opioid re-
ceptor as well as down-regulation of substance P/NK1
receptor.
GRe exerts an antioxidant potential, mitochondrial
restoration, and anti-apoptosis via protein kinase C δ
(PKCδ) inhibition in SH-SY5Y human neuroblastoma
cells [58]. Shin et al. [30] also demonstrated that GRe
rescued MA-induced oxidative damage, mitochondrial
dysfunction, microglial activation, and dopaminergic
degeneration by inhibiting PKCδ gene in mice. Previous
studies have reported that substance P facilitated the
phosphorylation of PKCδ in rat parotid acinar cells [78].
Moreover, it has been reported that PKCδ plays an im-
portant role in substance P-induced pro-inflammatory
signaling in human colonocytes [79]. Substance P-
induced PKCδ activation and its downstream signaling
pathway are dependent on NK1 receptor [80]. Wang
et al. [15] also identified PKCδ as a downstream signal
Fig. 9 Role of κ-opioid and neurokinin 1 receptors in GRe-mediated dopaminergic neuroprotection. Effects of neurokinin 1 receptor antagonist
L-733,060 on κ-opioid receptor antagonist Nor-B-mediated pharmacological activity in response to effects of GRe against changes in tyrosine
hydroxylase-immunoreactivity (TH-IR; a), TH expression (b), dopamine level (c), and dopamine turnover rate (d) induced by MA in the striatum of
DYN KO mice. Sal = saline, MA =methamphetamine 35 mg/kg, i.p., GRe = ginsenoside Re 20 mg/kg, i.p., Nor-B = Nor-binaltorphimine 3 or 6 mg/kg, i.p.,
L733 = L-733,060 5 or 10 mg/kg, i.p., WT =wild type, DYN KO = prodynorphin knockout. Each value is the mean ± SEM of six animals (one-way ANOVA
followed by Fisher’s LSD pairwise comparisons)
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that bridges substance P-mediated NK1 receptor activa-
tion and NOX2 activation in microglia. Therefore, it is
plausible that GRe modulates molecular interaction be-
tween substance P and PKCδ against MA insult.
Substance P is considered the prototype of the tachyki-
nin family and is encoded by the pre-protachykinin-A
gene. Substance P is the natural ligand that displays the
highest affinity for the NK1 receptor [6]. Earlier studies
have found that multiple administrations of MA elevated
the levels of pre-protachykinin-A mRNA and substance
P within striatonigral neurons, suggesting that exposure
to MA augments tachykinin neurotransmission in the
striatonigral pathway [81–83]. High levels of substance P
are present in the SN, where it binds to NK1 receptors
expressed on dopaminergic neurons [5]. Consistently,
we observed that treatment with MA resulted in a sig-
nificant increase in substance P-immunoreactivity. Previ-
ous research indicated that substance P binding at NK1
receptors expressed on microglia and astrocytes may dir-
ectly result in the activation of these glial cells in the
central nervous system [84, 85].
In this study, we observed that substance P localized
with neurons, astrocytes, or microglia after MA treat-
ment. In addition, treatment with MA resulted in
Fig. 10 A schematic depiction ginsenoside Re (GRe)-mediated dopaminergic neuroprotective effects against MA insult. Treatment with a toxic
dose of MA resulted in initial oxidative burdens, a perturbed redox status (a failure to compensate for reduced GPx) followed by the decreases in
dynorphin level and prodynorphin mRNA expression. This decrease led to imbalance between dynorphin and substance P and to enhance
substance P mRNA and substance P-immunoreactivity (SP-IR). At that time, SP-IR was co-localized in the Iba-1-immunoreactive microglia, NeuN-
immunoreactive neurons, and GFAP-immunoreactive astrocytes. More importantly, GRe did not affect MA-induced astrocytic expression (i.e., GFAP
expression), but GRe significantly attenuated against MA-induced microgliosis (i.e., Iba-1-immunoreactive-immunoreactivity and Iba-1 expression).
Neurokinin 1 receptor activation, genetic depletion of dynorphin, or κ-opioid receptor antagonism (i.e., nor-binaltorphimine) potentiated this
microgliosis, as well as pro-apoptotic changes. This morbid phenomenon contributed to dopaminergic impairment. Therefore, we propose that
GRe attenuates MA-induced neurotoxicity via upregulation of prodynorphin-mediated κ-opioid receptor and downregulation of substance P-mediated
NK1 receptor
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increases in GFAP and Iba-1 expression. The increase in
Iba-1 expression was attenuated by GRe or NK1 recep-
tor antagonist L-733,060, which was consequently coun-
teracted by κ-opioid receptor antagonist Nor-B.
However, L-733,060, but not GRe, affected GFAP
expression induced by MA. This finding supported pre-
vious study [15], suggesting that signaling events medi-
ated by GRe, dynorphin, or substance P are specific to
microglial cells.
Earlier study indicated that substance P and dynor-
phin co-exist extensively in specific populations of
striatal projection neurons, indicating a correlation
between two peptides [86]. Endogenous substance P
potentiates immunological activation of microglia in-
duced by lipopolysaccharide (LPS) or MPTP in the
SN, suggesting the critical role of substance P as an
inflammatory mediator in dopaminergic neurodegen-
eration [13, 14]. Block et al. [23] demonstrated a
tightly regulated mechanism governing microglia-
derived oxidative stress, in which the neuropeptide
balance of dynorphin and substance P is critical to
dopamine neuron survival. Substance P (10− 13–10−
14 M) is selectively toxic to dopaminergic neurons in
the presence of microglia, which was significantly
protected by dynorphin. In line with previous re-
search [23], here, we proposed that the interaction
between dynorphin and substance P may be essential
for modulating dopaminergic toxicity induced by a
single, high dose of MA (35 mg/kg, i.p.), indicating
critical roles of κ-opioid receptor and NK1 receptor
in modulating microglial activation.
Dopaminergic neurons in the SN are more susceptible
to oxidative and inflammatory insults than neurons in
other regions [87–90]. This phenomenon may be related
to a higher density of microglia in SN than in other
brain regions [91]. Similarly, a strong substance P-like
immunoreactivity [92–94] has been shown in SN, and
substance P is considered a likely neurotransmitter [95]
which excites neurons in SN [96]. Wang et al. [15] pro-
posed that substance P released from the nerve terminal
of striatonigral projections may contribute to the higher
microglial densities in the SN through the induction of
proliferation and/or through chemotaxic recruitment of
microglia. This is because the disproportionately higher
density of microglia and potential substance P itself in
the SN may contribute to the increased susceptibility of
nigral dopaminergic neurons to regional neuroinflamma-
tion [91, 97].
It has been well-recognized that macrophages/micro-
glia play different roles in tissue repair or damage in
response to CNS injury. Microglia in the brain have clas-
sically activated M1 phenotype or alternatively activated
M2 phenotype, depending on the inflammatory condi-
tions of the local microenvironment. MA treatment
enhanced the mRNA expression of M1 markers (CD16,
CD32, and CD86), while those of M2 markers (arginase
1 and CD206) were decreased [3]. Endogenous dynor-
phin depletion accelerated microglial differentiation to
the M1 phenotype after MA, suggesting that dynorphin
may serve to dampen this neuroinflammatory process
[3]. Importantly, treatment with GRe resulted in a sig-
nificant attenuation against MA-induced increase in
mRNA expression of M1 markers, indicating that GRe
possesses an anti-inflammatory effect [30].
Microgliosis has been traditionally considered to play
a passive role in the removal of dead or damaged neu-
rons and debris by phagocytosis [3]. However, it is clear
that microglial cells are reactivated during microgliosis,
and further exacerbate neurodegeneration under severe
inflammatory conditions [3]. It could be speculated that
the balance between dynorphin and substance P appears
to be critical for microglial activation and long-term sur-
vival of nigrostriatal dopaminergic neurons [23, 98]. Par-
allel with inducing microgliosis, MA can cause neuronal
proapoptosis, in addition to terminal degeneration, by
increasing caspase activity [55, 60, 99], current study].
Our earlier in vitro studies [98, 100] did not support
our current in vivo study. Kong et al. [100] demon-
strated that ultra-low concentrations (10− 12–10− 16 M)
of dynorphin A-(1–8) significantly inhibited the LPS-
induced production of NO or TNF-α in mixed glia cul-
tures. The inhibitory effects of dynorphin A-(1–8) were
not blocked by κ-opioid receptor antagonist Nor-B.
Similarly, LPS-induced neurotoxicity in rat midbrain
neuron-glia cultures was significantly reduced by treat-
ment with ultra-low concentrations (10− 13–10− 15 M) of
dynorphin A (1–17), but not by U50488, a synthetic κ-
opioid receptor agonist [98], suggesting that dynorphin-
mediated protective activity in vitro is not dependent on
κ-opioid receptor. This disparity between our in vivo
finding and previous in vitro reports remains to be fully
elucidated.
It is well known that NAc is more resistant to MA
toxicity [101], but the mechanism underlying the re-
gional heterogeneity of MA has not yet been fully eluci-
dated. The dopamine transporter (DAT) is believed to
be an essential component of pathway leading to MA
neurotoxicity in the striatum [102]. Supporting this no-
tion, the basal level of DAT binding sites is higher in
striatum than in NAc [6]. In addition, it was reported
that a toxic dose of MA caused the delayed increase of
glutamate release only in the striatum (caudate puta-
men), but not in the NAc [103]. A single injection of
amphetamine or MA increased mRNA levels of
preprotachykinin-A, along with preproenkephalin and
preprodynorphin (encoding the neuropeptides substance
P, enkephalines, and dynorphin, respectively) in the
neostriatum with far greater elevation in caudate
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putamen than in NAc [104, 105], suggesting the differ-
ential actions of peptide systems to MA in brain regions.
Observed regional differences between the caudate puta-
men and the NAc may reflect the existence of different
mechanisms of MA-induced toxicity operating in these
brain regions [6]. In addition, if nigrostriatal degener-
ation had occurred, MA treatment might activate micro-
glial activation in the SN. However, MA-induced
microglial activation in SN was much less than in
striatum (Additional file 1: Figure S5), suggesting that
MA-induced striatal burdens did not progress to ventral
midbrain. It was demonstrated that the extent of toxicity
within the ventral midbrain was greater in the SN pars
compacta then in the reticulate and ventral tegmental
area [106]. Rather, it is likely that the preservation of cel-
lular integrity of ventral midbrain is a critical factor that
allows for the recovery of the dopaminergic system
[107]. Consistently, whole ventral midbrain is also resist-
ant to MA toxicity in our experimental condition (please
refer to Table 1, Fig. 8, and Additional file 1: Figure S1).
GRe is a main ginsenoside and an important ingredi-
ent in ginseng leaf, berry, and root [24, 35, 36, 108]. Gin-
seng root has been mainly used as herbal medicine,
whereas other parts have been considered by-products
or minor products. Earlier reports indicated that GRe is
more abundant in the leaf, berry, and flower bud than in
the root [35, 36, 109], reflecting possible pharmaco-
economical advantages of GRe in terms of developing
natural/drug resources.
Conclusions
Our findings suggest that GRe exerts antioxidant, anti-
inflammatory, and anti-apoptotic potentials against MA-
induced dopaminergic neurotoxicity, and that interactive
modulation between dynorphin and substance P is es-
sential for GRe-mediated dopaminergic neuroprotection.
The promising efficacy of GRe in response to MA insult
may be helpful for developing therapeutic interventions
for disorders of dopaminergic degeneration, although
additional evidence should be obtained.
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